Phase 4 N=41 Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Mild Cognitive Impairment
Primary: Selective Reminding Test (SRT) — 33.61; 36.23; 36.81; 37.13 Words
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=121 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Alzheimer Disease · Mild Cognitive Impairment · Delirium, Dementia, Amnestic, Cognitive Disorders
Primary: Change Over Time in Selective Reminding Test (SRT) Scores — 36.14; 21.19; 39.99; 24.10 Words
N/A N=100 Smell Sensitivity in Chronic Migraine: A Case-Control Study
Chronic Migraine · Olfactory Acuity
Primary: Comparison of UPSIT Scores Between Subjects and Controls at Two Time Points — 34.5; 35.9; 34.7; 36.1 UPSIT Score
N/A N=29 Olfactory Contributions to Sleep-dependent Food Craving
Sleep Deprivation
Primary: Functional Magnetic Resonance Imaging (fMRI)-Based Decoding Accuracy of Food vs Non-food Odors in Piriform Cortex — 54.38; 49.65 Percentage correctly classified — p=0.001
N/A N=51 Steroid Nasal Irrigation for Flavor Evaluation and Detection Study
Olfactory Disorder
Primary: Pre- and Post-intervention Difference in Functional Connectivity Before and After Smell Training. — 5 Regions of interest
Phase 2 N=139 COVID-19 Anosmia Study
Anosmia · Covid19
Primary: Change in Brief Smell Identification Test (BSIT) — 6.77; 7.20; 7.89; 7.88 score on a scale
Phase 4 N=102 Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis
Allergic Rhinitis
Primary: Product Preference Questionnaire for Immediate Taste — 26.47; 10.78; 5.88; 15.69 Percentage of participants
N/A N=92 Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals
Feeding Behavior · Obesity · Overweight
Primary: Change in Food Image Ratings — -5.1; -.3; -6.8; -2.7 Score change from baseline — p=0.038
Phase 2 N=48 Stellate Ganglion Block for COVID-induced Parosmia
COVID-19-Induced Parosmia
Primary: Parosmia Olfactory Dysfunction Outcomes Rating — 9; 9; 14; 11 score on a scale 0-112
Phase 4 N=32 Intranasal Oxytocin and Social Cognition, Implicit Preferences and Craving in Alcohol Drinkers
AOD Use, Abuse, and Dependence
Primary: Change in Craving on the Alcohol Urge Questionnaire (AUQ) After Administration of Oxytocin vs. Placebo During the 3-week Study. — 1.11; 0.69 units on a 7-pt Likert Scale
N/A N=50 Evaluation of Smell and Taste in Fibromyalgia
Fibromyalgia
Primary: Sniffin' Sticks Test Score — 25.96; 36.40 score on a scale
Phase 2 N=51 Smell in Covid-19 and Efficacy of Nasal Theophylline
Covid19 · Anosmia · Olfactory Disorder
Primary: UPSIT — 59; 43 percentage of participants
N/A N=16 Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
Nutritional and Metabolic Diseases
Primary: Number of Test Results Outside the Normal Range — 6; 3; 0; 0 participants
N/A N=1,320 Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects
COVID-19
Primary: Sensitivity, Specificity and Accuracy — 889; 106; 27; 20 Participants
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=30 Acupuncture Therapy for COVID-Related Olfactory Loss
Olfactory Dysfunction · COVID-19
Primary: Change in University of Pennsylvania Smell Identification Test (UPSIT) Scores — 2.571; 3.182 score on a scale
Phase 1 N=56 The Effects of Smell on Mood and Physical Responses
Stress · Anxiety · Depression
Primary: Cortisol and Catecholamine Production — 0.107; 0.119; 0.107; 43.5 pg/ml (log 10) — p=0.83
Phase 2 N=20 Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Anosmia · Hyposmia · Parosmia
Primary: Clinical Global Impression - Improvement (CGI-I) Score — 12; 8; 0; 0 Participants
N/A N=58 Symptom Perception
Asthma
Primary: Asthma Control Questionnaire (ACQ) — 1.2; 1.4; 0.8; 1.4 score on a scale
Phase 2 N=7 Helping Olfaction and Nutrition On Renal Replacement
End Stage Renal Disease · Olfactory Disorders
Primary: Change From Baseline in Smell Identification Test Score at 6 Weeks — 4 units on a scale
Early Phase 1 N=26 Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception
Social Perception
Primary: Amplitude Social — -3.72; -3.55; -3.28; -3.30 microvolts — p=.003
N/A N=47 Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety
Social Intelligence
Primary: Affective Ratings in Affective Learning Task — -0.096; -0.12 units on a scale
N/A N=125 Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions
Nutritional and Metabolic Diseases
Primary: Gut Microbiome — 52; 64; 25; 33 Normalized OTU counts
Phase 2 N=68 Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
COVID-19 · Olfactory Disorder · Anosmia
Primary: Clinical Global Impression of Improvement Scale (CGI-I) — 8; 20; 7; 12 Participants
Phase 2 N=27 Smell Changes & Efficacy of Nasal Theophylline
Olfactory Disorder · Anosmia · Viral Infection
Primary: Number of Patients With Improvement in Global Rating of Smell Change — 4; 3 Participants
N/A N=44 Oxytocin and Approach-avoid in Grief
Prolonged Grief Disorder · Bereavement
Primary: Reaction Time (ms) of a Push or Pull of a Joystick in a Standard Interactive Approach/Avoid Task. — 29; 18; 7.5; 13.0 Milliseconds (contrast score)
Phase 2 N=77 Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)
COVID-19
Primary: Clinical Global Impression - Improvement Scale — 9; 9 Participants
N/A N=40 Fat Perception in Humans (09-0873)
Obesity
Primary: Oleic Acid Detection Level — -0.3; -1.2; -1.0 log10 (%W/V OLEIC ACID) — p=0.05
N/A N=31 Water Content in E-Liquids
Nicotine E-Cigarette Use
Primary: Irritation/Harshness — 1.04; 1.07; 1.03; 1.01 units on a scale — p=0.0014
N/A N=97 Sensitive Periods in Human Flavor Learning
Development
Primary: Vegetable Flavor Acceptance [Infants' Intake] — 56.8; 42.4; 29.0; 40.7 intake in grams — p=0.02